Liminatus Pharma Inc Cl A (LIMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 338 | 725 | 1,338 | N/A | 56 |
| Receivables | N/A | N/A | N/A | N/A | 3,669 |
| Other current assets | 0 | 0 | 0 | 0 | 1,401 |
| TOTAL | $501 | $1,203 | $1,782 | $N/A | $5,282 |
| Non-Current Assets | |||||
| PPE Net | 12 | 13 | 0 | N/A | 1 |
| Other Non-Current Assets | 0 | 126 | 126 | 0 | 126 |
| TOTAL | $12 | $139 | $127 | $N/A | $127 |
| Total Assets | $513 | $1,342 | $1,909 | $N/A | $5,409 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,443 | 1,443 | 1,443 | N/A | 19,973 |
| Accounts payable and accrued liabilities | 8,152 | 737 | 603 | 0 | 3,461 |
| Accrued Expenses | 204 | 185 | 166 | 1 | 955 |
| Other current liabilities | 500 | 500 | 8,305 | N/A | N/A |
| TOTAL | $10,298 | $2,865 | $10,516 | $1 | $24,749 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 29 | 124 | 201 | 0 | 0 |
| TOTAL | $29 | $124 | $201 | $N/A | $N/A |
| Total Liabilities | $10,328 | $2,988 | $10,716 | $1 | $24,749 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 44,878 | 27,065 | 27,065 | 26,015 | N/A |
| Common Shares | 3 | 3 | 3 | N/A | 2 |
| Retained earnings | -38,872 | -30,703 | -28,880 | -1 | -28,665 |
| TOTAL | $-9,815 | $-1,646 | $-8,807 | $-1 | $-19,340 |
| Total Liabilities And Equity | $513 | $1,342 | $1,909 | $0 | $5,409 |